| Q41661043 | "Dicing and Splicing" Sphingosine Kinase and Relevance to Cancer. |
| Q33598692 | 4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1. |
| Q61942652 | A Circadian Rhythm in both Complement Cascade (ComC) Activation and Sphingosine-1-Phosphate (S1P) Levels in Human Peripheral Blood Supports a Role for the ComC-S1P Axis in Circadian Changes in the Number of Stem Cells Circulating in Peripheral Blood |
| Q41972670 | A complex extracellular sphingomyelinase of Pseudomonas aeruginosa inhibits angiogenesis by selective cytotoxicity to endothelial cells |
| Q33855120 | A novel function of sphingosine kinase 1 suppression of JNK activity in preventing inflammation and injury |
| Q33988392 | A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: implication for treating hyperproliferative disorders |
| Q27009351 | A review of ceramide analogs as potential anticancer agents |
| Q41931868 | ABC294640, a novel sphingosine kinase 2 inhibitor induces oncogenic virus infected cell autophagic death and represses tumor growth |
| Q52663621 | ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. |
| Q42386819 | AICAR inhibits ceramide biosynthesis in skeletal muscle |
| Q39026397 | ASP0028 in combination with suboptimal-dose of tacrolimus in Cynomolgus monkey renal transplantation model |
| Q30827729 | Ablation of Sphingosine 1-Phosphate Receptor Subtype 3 Impairs Hippocampal Neuron Excitability In vitro and Spatial Working Memory In vivo |
| Q30303094 | Abluminal stimulation of sphingosine 1-phosphate receptors 1 and 3 promotes and stabilizes endothelial sprout formation |
| Q35522175 | Activated platelets release sphingosine 1-phosphate and induce hypersensitivity to noxious heat stimuli in vivo. |
| Q90228330 | Activation of the Sphingosine 1 Phosphate-Rho Pathway in Pterygium and in Ultraviolet-Irradiated Normal Conjunctiva |
| Q34125349 | Adiponectin signaling in the liver |
| Q34137322 | Advances in the management of peritoneal mesothelioma |
| Q36664563 | Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. |
| Q46135175 | Altered Leukocyte Sphingolipid Pathway in Breast Cancer. |
| Q45065681 | An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors. |
| Q37076525 | Analysis of inflammatory and lipid metabolic networks across RAW264.7 and thioglycolate-elicited macrophages |
| Q36049681 | Analysis of sphingosine kinase activity in single natural killer cells from peripheral blood. |
| Q52684278 | Anti-CD69 therapy induces rapid mobilization and high proliferation of HSPCs through S1P and mTOR. |
| Q36374498 | Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model |
| Q35011925 | Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma |
| Q47232359 | Apolipoprotein M Inhibits Angiogenic and Inflammatory Response by Sphingosine 1-Phosphate on Retinal Pigment Epithelium Cells. |
| Q42701208 | Arsonists and firefighters: the perpetual inflammatory civil war for survival |
| Q27000801 | Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) |
| Q55030990 | Autophagy and Its Interaction With Intracellular Bacterial Pathogens. |
| Q35945545 | BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. |
| Q34020834 | Basal release of ATP: an autocrine-paracrine mechanism for cell regulation |
| Q27667249 | Biochemical and Structural Characterization of Lysophosphatidic Acid Binding by a Humanized Monoclonal Antibody |
| Q28486289 | Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent |
| Q36830558 | Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic beta-cells |
| Q41089511 | Breast cancer sphingosine-1-phosphate is associated with phospho-sphingosine kinase 1 and lymphatic metastasis |
| Q33593619 | Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects |
| Q35897043 | Cell density-dependent reduction of dihydroceramide desaturase activity in neuroblastoma cells. |
| Q64904602 | Ceramide and Exosomes: A Novel Target in Cancer Biology and Therapy. |
| Q41533503 | Ceramide and insulin resistance: how should the issue be approached? |
| Q55002300 | Ceramide species are elevated in human breast cancer and are associated with less aggressiveness. |
| Q38124070 | Ceramides in the pathophysiology of the anterior segment of the eye. |
| Q30361278 | Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression. |
| Q28483643 | Characterization of isoenzyme-selective inhibitors of human sphingosine kinases |
| Q42397403 | Characterization of sphingosine-1-phosphate lyase activity by electrospray ionization-liquid chromatography/tandem mass spectrometry quantitation of (2E)-hexadecenal |
| Q40080527 | Cigarette smoke inhibits efferocytosis via deregulation of sphingosine kinase signaling: reversal with exogenous S1P and the S1P analogue FTY720. |
| Q47996348 | Classification of sphingosine kinase inhibitors using counter propagation artificial neural networks: A systematic route for designing selective SphK inhibitors |
| Q41622885 | Clinical Impact of Sphingosine-1-Phosphate in Breast Cancer |
| Q54662271 | Complementary effects of ciclopirox olamine, a prolyl hydroxylase inhibitor and sphingosine 1-phosphate on fibroblasts and endothelial cells in driving capillary sprouting. |
| Q28250778 | Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression |
| Q34399068 | Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids |
| Q38619642 | DNA damage response and sphingolipid signaling in liver diseases |
| Q37415213 | Dendritic cell sphingosine-1-phosphate lyase regulates thymic egress |
| Q30417604 | Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors |
| Q39517521 | Determination of sphingosine kinase 2 activity using fluorescent sphingosine by capillary electrophoresis |
| Q22305854 | Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach |
| Q89847027 | Differential contribution of sensory transient receptor potential channels in response to the bioactive lipid sphingosine-1-phosphate |
| Q48455938 | Differential modulation of S1PR(1-5) and specific activities of SphK and nSMase in pulmonary and cerebral tissues of rats exposed to hypobaric hypoxia |
| Q58772957 | Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity |
| Q34555185 | Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels |
| Q37830235 | Dissecting the role of the S1P/S1PR axis in health and disease. |
| Q52671501 | Divergent Role of Sphingosine 1-Phosphate in Liver Health and Disease. |
| Q45071199 | Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. |
| Q39648906 | Dupuytren's Fibroblast Contractility by Sphingosine-1-Phosphate Is Mediated Through Non-Muscle Myosin II |
| Q35078615 | Effects of inhibition of serine palmitoyltransferase (SPT) and sphingosine kinase 1 (SphK1) on palmitate induced insulin resistance in L6 myotubes |
| Q58751451 | Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO |
| Q37341131 | Emerging Role of Sphingosine-1-phosphate in Inflammation, Cancer, and Lymphangiogenesis |
| Q37965547 | Emerging oral drugs for relapsing-remitting multiple sclerosis. |
| Q35975127 | Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy |
| Q48158764 | Endurance training selectively increases high-density lipoprotein-bound sphingosine-1-phosphate in the plasma |
| Q39774569 | Enhancement of sphingosine kinase 1 catalytic activity by deletion of 21 amino acids from the COOH-terminus |
| Q51147812 | Enhancement of wound closure by modifying dual release patterns of stromal-derived cell factor-1 and a macrophage recruitment agent from gelatin hydrogels. |
| Q39577061 | Enigmol: a novel sphingolipid analogue with anticancer activity against cancer cell lines and in vivo models for intestinal and prostate cancer |
| Q34104555 | Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers |
| Q36748690 | Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression and activity in cancer |
| Q33796082 | Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. |
| Q53084249 | Exogenous sphingosine 1-phosphate protects murine splenocytes against hypoxia-induced injury. |
| Q37408557 | Export and functions of sphingosine-1-phosphate. |
| Q27009557 | Export of sphingosine-1-phosphate and cancer progression |
| Q35889923 | Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer |
| Q36320677 | Expression of sphingosine 1-phosphate receptors in the rat dorsal root ganglia and defined single isolated sensory neurons |
| Q34183703 | Extracellular and Intracellular Actions of Sphingosine-1-Phosphate |
| Q34162587 | FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells |
| Q35819965 | FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans |
| Q33854428 | FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. |
| Q34718530 | FTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons. |
| Q34551954 | Fenretinide causes emphysema, which is prevented by sphingosine 1-phoshate |
| Q37765473 | Fingolimod is a potential novel therapy for multiple sclerosis |
| Q48649157 | Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide |
| Q37851885 | Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis |
| Q98471366 | Follicle-stimulating hormone promotes the proliferation of epithelial ovarian cancer cells by activating sphingosine kinase |
| Q43984955 | Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer |
| Q90296101 | Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis |
| Q33831886 | Genetic evidence for involvement of neuronally expressed S1P₁ receptor in nociceptor sensitization and inflammatory pain |
| Q39624007 | Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants |
| Q35845653 | Growth and metabolism of Beauveria bassiana spores and mycelia |
| Q35238369 | High density lipoprotein stimulated migration of macrophages depends on the scavenger receptor class B, type I, PDZK1 and Akt1 and is blocked by sphingosine 1 phosphate receptor antagonists |
| Q40964594 | High levels of sphingolipids in human breast cancer. |
| Q40567317 | Host sphingosine kinase 1 worsens pancreatic cancer peritoneal carcinomatosis |
| Q38307041 | Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes sphingosine 1-phosphate, a central mediator of angiogenesis |
| Q37233204 | Immunosuppressive human anti-lymphocyte autoantibodies specific for the type 1 sphingosine 1-phosphate receptor |
| Q42966392 | Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis. |
| Q36898368 | Implication of sphingosin-1-phosphate in cardiovascular regulation |
| Q37662940 | Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis |
| Q38162168 | Inflammatory and microenvironmental factors involved in breast cancer progression |
| Q35661331 | Inhibition of Sphingosine Kinase 1 Ameliorates Angiotensin II-Induced Hypertension and Inhibits Transmembrane Calcium Entry via Store-Operated Calcium Channel |
| Q88990558 | Innate lymphoid cells-key immune integrators of overall body homeostasis |
| Q34373466 | Interdiction of sphingolipid metabolism to improve standard cancer therapies |
| Q92630730 | Interleukin-22 Mediates the Chemotactic Migration of Breast Cancer Cells and Macrophage Infiltration of the Bone Microenvironment by Potentiating S1P/SIPR Signaling |
| Q33386012 | Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection |
| Q37100281 | Interstitial Fluid Sphingosine-1-Phosphate in Murine Mammary Gland and Cancer and Human Breast Tissue and Cancer Determined by Novel Methods |
| Q28743138 | Intracellular S1P generation is essential for S1P-induced motility of human lung endothelial cells: role of sphingosine kinase 1 and S1P lyase |
| Q34053079 | Intracellular localization of sphingosine kinase 1 alters access to substrate pools but does not affect the degradative fate of sphingosine-1-phosphate |
| Q35830897 | Inverse-phosphocholine lipids: a remix of a common phospholipid |
| Q36369205 | Involvement of Band3 in the efflux of sphingosine 1-phosphate from erythrocytes |
| Q46049440 | Involvement of the ABC-transporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P(3) in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone |
| Q40341970 | Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)? |
| Q39565607 | KAI1 inhibits HGF-induced invasion of pancreatic cancer by sphingosine kinase activity. |
| Q36607525 | Legionella pneumophila S1P-lyase targets host sphingolipid metabolism and restrains autophagy |
| Q92257208 | Light Stress-Induced Increase of Sphingosine 1-Phosphate in Photoreceptors and Its Relevance to Retinal Degeneration |
| Q37173179 | Lipid phosphate phosphatases and signaling |
| Q28088430 | Lipid phosphate phosphatases and their roles in mammalian physiology and pathology |
| Q34269858 | Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. |
| Q91823189 | Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia |
| Q37414484 | Lyase to live by: sphingosine phosphate lyase as a therapeutic target |
| Q34084937 | Lymphangiogenesis: A new player in cancer progression |
| Q47233200 | Lysophosphatidic Acid Signaling Axis Mediates Ceramide 1-Phosphate-Induced Proliferation of C2C12 Myoblasts |
| Q99418917 | MYPT1 O-GlcNAc modification regulates sphingosine-1-phosphate mediated contraction |
| Q97644512 | Macrophage Sphingosine 1-Phosphate Receptor 2 Blockade Attenuates Liver Inflammation and Fibrogenesis Triggered by NLRP3 Inflammasome |
| Q33829692 | Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget |
| Q92961499 | Manipulation of the Sphingolipid Rheostat Influences the Mediator of Flow-Induced Dilation in the Human Microvasculature |
| Q37457462 | Maternal fumonisin exposure as a risk factor for neural tube defects |
| Q37154242 | Mechanisms linking obesity and cancer |
| Q36377252 | Mechanisms of lipotoxicity in the cardiovascular system |
| Q38713803 | Mechanisms of sphingosine-1-phosphate-mediated vasoconstriction of rat afferent arterioles |
| Q30413877 | Memo has a novel role in S1P signaling and is [corrected] crucial for vascular development |
| Q42120428 | MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma |
| Q33636763 | Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. |
| Q93335813 | Molecular mechanisms of biogenesis of apoptotic exosome-like vesicles and their roles as damage-associated molecular patterns |
| Q41829826 | Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat. |
| Q36355889 | Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids |
| Q28078299 | NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications |
| Q41127962 | NMR metabolomics highlights sphingosine kinase-1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells |
| Q35955451 | Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer |
| Q37588466 | Noncanonical transforming growth factor beta signaling in scleroderma fibrosis |
| Q33684331 | Normalization of diabetic wound healing |
| Q92012755 | Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases |
| Q37925819 | Nuclear sphingolipid metabolism |
| Q38092176 | Oncogenic properties of sphingosine kinases in haematological malignancies. |
| Q43838770 | Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system |
| Q87417830 | Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice |
| Q36996563 | Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management |
| Q64076938 | Osteoporosis and skeletal dysplasia caused by pathogenic variants in SGMS2 |
| Q37660877 | Outside the box signaling: secreted factors modulate GnRH receptor-mediated gonadotropin regulation |
| Q36410748 | Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice |
| Q38960964 | Oxidized LDL-induced angiogenesis involves sphingosine 1-phosphate: prevention by anti-S1P antibody |
| Q45073187 | Paradoxical Association of Postoperative Plasma Sphingosine-1-Phosphate with Breast Cancer Aggressiveness and Chemotherapy. |
| Q44324305 | Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model |
| Q35130512 | Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system |
| Q38763707 | Platelet-derived sphingosine-1-phosphate and inflammation: from basic mechanisms to clinical implications |
| Q37782076 | Polymer-drug conjugates for novel molecular targets |
| Q37002064 | Potential signaling pathway involved in sphingosine-1-phosphate-induced epithelial-mesenchymal transition in cancer |
| Q88961948 | Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells |
| Q37658857 | Radiation countermeasure agents: an update |
| Q35101294 | Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. |
| Q34559806 | Regulating survival and development in the retina: key roles for simple sphingolipids |
| Q35683960 | Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes |
| Q37415111 | Regulation of vascular physiology and pathology by the S1P2 receptor subtype. |
| Q57802697 | Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse |
| Q38262594 | Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease |
| Q34574599 | Role for peroxynitrite in sphingosine-1-phosphate-induced hyperalgesia in rats |
| Q90341490 | Role of Bioactive Sphingolipids in Inflammation and Eye Diseases |
| Q58760187 | Role of S1P/S1PR3 axis in release of CCL20 from human bronchial epithelial cells |
| Q92009926 | Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Axis in Hepatocellular Carcinoma |
| Q40990718 | Role of Sphingosine-1-Phosphate in Transplant Vasculopathy Evoked by Anti-HLA Antibody |
| Q64891856 | Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke. |
| Q39506935 | Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells |
| Q34879183 | Roles of sphingosine 1-phosphate on tumorigenesis |
| Q37699303 | Roles of sphingosine-1-phosphate in reproduction |
| Q91738678 | Roles of sphingosine-1-phosphate signaling in cancer |
| Q39169246 | Runx1 Orchestrates Sphingolipid Metabolism and Glucocorticoid Resistance in Lymphomagenesis. |
| Q38626918 | S1P Provokes Tumor Lymphangiogenesis via Macrophage-Derived Mediators Such as IL-1β or Lipocalin-2. |
| Q35136728 | S1P is associated with protection in human and experimental cerebral malaria |
| Q33886533 | S1P metabolism in cancer and other pathological conditions |
| Q42735904 | S1P promotes breast cancer progression by angiogenesis and lymphangiogenesis |
| Q48849226 | S1P prophylaxis mitigates acute hypobaric hypoxia-induced molecular, biochemical, and metabolic disturbances: A preclinical report |
| Q38703649 | S1P receptor 1-Mediated Anti-Renin-Angiotensin System Cardioprotection: Pivotal Role of Mast Cell Aldehyde Dehydrogenase Type 2. |
| Q35633763 | S1P-Dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection |
| Q91782570 | S1P-S1PR1 Signaling: the "Sphinx" in Osteoimmunology |
| Q92914007 | SGPL1321 mutation: one main trigger for invasiveness of pediatric alveolar rhabdomyosarcoma |
| Q37997376 | Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis. |
| Q34345362 | Single-cell sphingosine kinase activity measurements in primary leukemia |
| Q35776618 | Sources, metabolism, and regulation of circulating sphingosine-1-phosphate |
| Q35138620 | Space radiation-associated lung injury in a murine model |
| Q92347503 | Sphingolipid metabolism and drug resistance in ovarian cancer |
| Q89977951 | Sphingolipids and Mitochondrial Dynamic |
| Q45072496 | Sphingolipids and Redox Signaling in Renal Regulation and Chronic Kidney Diseases |
| Q64965708 | Sphingolipids as Emerging Mediators in Retina Degeneration. |
| Q37527497 | Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system |
| Q26773230 | Sphingolipids in High Fat Diet and Obesity-Related Diseases |
| Q49972804 | Sphingolipids role in the regulation of inflammatory response: From leukocyte biology to bacterial infection |
| Q47095059 | Sphingosine 1-Phosphate- and C-C Chemokine Receptor 2-Dependent Activation of CD4+ Plasmacytoid Dendritic Cells in the Bone Marrow Contributes to Signs of Sepsis-Induced Immunosuppression |
| Q36636026 | Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways |
| Q35921615 | Sphingosine 1-phosphate (S1P) regulates glucose-stimulated insulin secretion in pancreatic beta cells |
| Q34121255 | Sphingosine 1-phosphate and cancer |
| Q38223679 | Sphingosine 1-phosphate and cancer: lessons from thyroid cancer cells |
| Q34474499 | Sphingosine 1-phosphate modulates antigen capture by murine Langerhans cells via the S1P2 receptor subtype |
| Q36532321 | Sphingosine 1-phosphate receptor 2 antagonist JTE-013 increases the excitability of sensory neurons independently of the receptor |
| Q27024207 | Sphingosine 1-phosphate signaling pathway in inner ear biology. New therapeutic strategies for hearing loss? |
| Q41980318 | Sphingosine 1-phosphate to p38 signaling via S1P1 receptor and Gαi/o evokes augmentation of capsaicin-induced ionic currents in mouse sensory neurons. |
| Q38185438 | Sphingosine 1-phosphate: a potential molecular target for ovarian cancer therapy? |
| Q47121464 | Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer |
| Q30275552 | Sphingosine Kinase 2 Deficiency Attenuates Kidney Fibrosis via IFN-γ. |
| Q35845319 | Sphingosine Kinase 2 and Ceramide Transport as Key Targets of the Natural Flavonoid Luteolin to Induce Apoptosis in Colon Cancer Cells |
| Q42233131 | Sphingosine analog AAL-R promotes activation of LCMV-infected dendritic cells |
| Q33727889 | Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro |
| Q42149287 | Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways |
| Q54565672 | Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death. |
| Q38937332 | Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer |
| Q27303619 | Sphingosine kinase 1 deficiency exacerbates LPS-induced neuroinflammation |
| Q45070648 | Sphingosine kinase 1 in breast cancer |
| Q38013700 | Sphingosine kinase 1 in viral infections. |
| Q39168123 | Sphingosine kinase 1 overexpression stimulates intestinal epithelial cell proliferation through increased c-Myc translation |
| Q38333309 | Sphingosine kinase 1/S1P pathway involvement in the GDNF-induced GAP43 transcription |
| Q46726983 | Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis |
| Q64933352 | Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo. |
| Q37328806 | Sphingosine kinase regulation and cardioprotection |
| Q33586246 | Sphingosine kinase-1 (SphK-1) regulates Mycobacterium smegmatis infection in macrophages |
| Q37208958 | Sphingosine kinase-1, S1P transporter spinster homolog 2 and S1P2 mRNA expressions are increased in liver with advanced fibrosis in human |
| Q43269484 | Sphingosine kinase-1: a potential mediator of renal fibrosis |
| Q89987678 | Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1 |
| Q35204641 | Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells |
| Q38408286 | Sphingosine kinases/sphingosine-1-phosphate and death Signalling in APP-transfected cells |
| Q38115668 | Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system? |
| Q37405258 | Sphingosine phosphate lyase regulates myogenic differentiation via S1P receptor-mediated effects on myogenic microRNA expression |
| Q91801206 | Sphingosine-1-Phosphate Facilitates Skin Wound Healing by Increasing Angiogenesis and Inflammatory Cell Recruitment with Less Scar Formation |
| Q35996098 | Sphingosine-1-Phosphate Lyase Deficient Cells as a Tool to Study Protein Lipid Interactions |
| Q26766425 | Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential |
| Q26775993 | Sphingosine-1-Phosphate and Its Receptors: A Mutual Link between Blood Coagulation and Inflammation |
| Q35059057 | Sphingosine-1-phosphate acting via the S1P₁ receptor is a downstream signaling pathway in ceramide-induced hyperalgesia |
| Q34474363 | Sphingosine-1-phosphate and immune regulation: trafficking and beyond |
| Q37176189 | Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts |
| Q26852824 | Sphingosine-1-phosphate in chronic intestinal inflammation and cancer |
| Q37543777 | Sphingosine-1-phosphate in the lymphatic fluid determined by novel methods |
| Q34251293 | Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. |
| Q38953409 | Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation |
| Q91863467 | Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain |
| Q37726630 | Sphingosine-1-phosphate receptor 1 reporter mice reveal receptor activation sites in vivo |
| Q35146069 | Sphingosine-1-phosphate receptor 2 |
| Q35121901 | Sphingosine-1-phosphate receptor 3 mediates sphingosine-1-phosphate induced release of weibel-palade bodies from endothelial cells. |
| Q30435328 | Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS |
| Q50861734 | Sphingosine-1-phosphate signalling-a key player in the pathogenesis of Angiotensin II-induced hypertension. |
| Q37358457 | Sphingosine-1-phosphate synthesis and functions in mast cells |
| Q42181059 | Sphingosine-1-phosphate transporters as targets for cancer therapy. |
| Q48547561 | Sphingosine-1-phosphate, regulated by FSH and VEGF, stimulates granulosa cell proliferation. |
| Q46119380 | Sphingosine-1-phosphate-induced nociceptor excitation and ongoing pain behavior in mice and humans is largely mediated by S1P3 receptor |
| Q50665340 | Sphingosine-1-phosphate/sphingosine kinase 1-dependent lymph node metastasis in esophageal squamous cell carcinoma. |
| Q90117111 | Sphingosine-1-phosphate: From insipid lipid to a key regulator |
| Q37697043 | Sphk1 promotes breast epithelial cell proliferation via NF-κB-p65-mediated cyclin D1 expression |
| Q28482973 | StarD7 knockdown modulates ABCG2 expression, cell migration, proliferation, and differentiation of human choriocarcinoma JEG-3 cells |
| Q89162813 | Survival benefit of sphingosin-1-phosphate and receptors expressions in breast cancer patients |
| Q37501281 | Symbiont-derived sphingolipids modulate mucosal homeostasis and B cells in teleost fish |
| Q37397209 | Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro |
| Q91713570 | T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer? |
| Q35831148 | TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis |
| Q35935087 | TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism |
| Q42380774 | Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation |
| Q37172893 | Targeting SphK1 as a new strategy against cancer |
| Q57399036 | Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss |
| Q37894772 | Targeting sphingosine-1-phosphate receptors in cancer |
| Q39379449 | Targeting sphingosine-1-phosphate signaling for cancer therapy |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q34217756 | The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. |
| Q26748848 | The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined |
| Q27657731 | The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen |
| Q62272072 | The emerging alliance of sphingosine-1-phosphate signalling and immune cells: from basic mechanisms to implications in hypertension |
| Q26748927 | The emerging role of FTY720 (Fingolimod) in cancer treatment |
| Q34094557 | The immunosuppressant FTY720 (fingolimod) enhances glycosaminoglycan depletion in articular cartilage |
| Q37688434 | The interplay between bioactive sphingolipids and steroid hormones |
| Q36011196 | The outs and the ins of sphingosine-1-phosphate in immunity |
| Q37319760 | The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. |
| Q38694191 | The role of Lutheran/basal cell adhesion molecule in human bladder carcinogenesis. |
| Q34271986 | The role of adiponectin in cancer: a review of current evidence |
| Q45051424 | The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice |
| Q36241051 | The role of sphingosine-1-phosphate in breast cancer tumor-induced lymphangiogenesis. |
| Q57153732 | The role of sphingosine-1-phosphate in inflammation and cancer progression |
| Q38734489 | The role of sphingosine-1-phosphate in the tumor microenvironment and its clinical implications. |
| Q38909010 | The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. |
| Q34379689 | The sphingosine 1-phosphate receptor, S1PR₁, plays a prominent but not exclusive role in enhancing the excitability of sensory neurons |
| Q34986940 | The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension |
| Q48349932 | The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. |
| Q39251134 | The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism |
| Q39253082 | The sphingosine kinase inhibitor N,N-dimethylsphingosine inhibits neointimal hyperplasia |
| Q38915115 | Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism |
| Q34527281 | Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer |
| Q37930972 | Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer |
| Q38909416 | Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. |
| Q37071804 | Transcriptional modulation of SLC26A3 (DRA) by sphingosine-1-phosphate. |
| Q59354243 | Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice |
| Q33635116 | Twofer anti-vascular therapy targeting sphingosine-1-phosphate for breast cancer. |
| Q30353137 | Up-regulation of tumor suppressor genes by exogenous dhC16-Cer contributes to its anti-cancer activity in primary effusion lymphoma. |
| Q37293908 | Vascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammation |
| Q39005334 | Vitamin D therapy in experimental allergic encephalomyelitis could be limited by opposing effects of sphingosine 1-phosphate and gelsolin dysregulation. |
| Q33773550 | Why is effective treatment of asthma so difficult? An integrated systems biology hypothesis of asthma |
| Q51831879 | β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling. |